It would also be interesting to evaluate if treatment with ruxolitinib, an agent with anti-inflammatory and immunosuppressive properties, can prevent thrombosis in patients with MPN given the reduction of pro-inflammatory cytokines, including IL-6, as a result of its JAK1 inhibitory action [18]. This evidence concerns the gene JAK1 and myeloproliferative disorder.